Tau Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Tau (tubulin-associated unit) is a microtubule-associated protein (MAP) primarily expressed in neurons of the central nervous system, where it plays essential roles in microtubule stabilization, axonal transport, and neuronal cytoskeletal integrity. Encoded by the [MAPT gene] on chromosome 17q21, tau is a natively unfolded protein that becomes pathologically hyperphosphorylated and aggregated in a broad class of neurodegenerative diseases collectively termed tauopathies (Goedert & Spillantini, 2019).
In Alzheimer's Disease (AD), tau forms neurofibrillary tangles[3] (NFTs) composed of paired helical filaments (PHFs) and straight filaments (SFs), and the burden of tau pathology correlates more closely with cognitive decline and neuronal loss than amyloid-beta (Aβ plaques (Nelson et al., 2012). Beyond AD, tau aggregation drives neurodegeneration in Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Pick's disease, chronic traumatic encephalopathy (CTE), frontotemporal dementia, and numerous other conditions. Tau is now a major therapeutic target, with multiple immunotherapies, antisense oligonucleotides, and small molecule inhibitors in clinical trials (tau-targeted therapeutics](/treatments/tau-targeted-therapeutics)).
The [MAPT gene] spans approximately 150 kb and contains 16 exons. Through alternative splicing of exons 2, 3, and 10, six tau isoforms are produced in the adult human brain (Buchholz et al., 2024):
| Isoform | Amino Acids | N-terminal Inserts | Repeat Domains | Approximate Brain Expression |
|---|---|---|---|---|
| 0N3R | 352 | None | 3 (R1, R3, R4) | ~9% |
| 1N3R | 381 | 1 (exon 2) | 3 | ~8% |
| 2N3R | 410 | 2 (exons 2+3) | 3 | ~9% |
| 0N4R | 383 | None | 4 (R1-R4) | ~11% |
| 1N4R | 412 | 1 (exon 2) | 4 | ~54% |
| 2N4R | 441 | 2 (exons 2+3) | 4 | ~9% |
In the healthy adult brain, 3R and 4R isoforms are expressed at approximately equal ratios (~1:1). Perturbation of this ratio is pathogenic: increased 4R expression causes 4R tauopathies (PSP, [CBD), while mutations affecting exon 10 splicing alter the 3R:4R balance and cause frontotemporal dementia (Hutton et al., 1998).
The MAPT locus contains a ~900 kb inversion polymorphism:
In the fetal brain, only the shortest isoform (0N3R) is expressed. The transition to adult 6-isoform expression occurs during postnatal development and is regulated by splicing factors including SRSF2, TRA2B, and PTBP1. This developmental switch is relevant to neurodegeneration as fetal tau is more heavily phosphorylated than adult tau.
Tau is an intrinsically disordered protein (IDP) that lacks a stable globular structure in solution. Its structure can be divided into four functional regions:
N-terminal projection domain (residues 1-150): Projects from the microtubule surface; contains the N-terminal inserts (N1, N2); interacts with the plasma membrane, [annexin A2], and signaling molecules; acts as a spacer between microtubules[2]
Proline-rich region (residues 151-243): Contains seven PXXP motifs that mediate interactions with SH3-domain-containing proteins such as [Fyn kinase], phospholipase C-gamma, and Src family kinases; crucial for signaling at the postsynaptic density
Microtubule-binding domain (MTBD) (residues 244-368): Contains the four imperfect repeat sequences (R1-R4, each ~31-32 amino acids) plus flanking regions; directly binds and stabilizes microtubules[2]; the inter-repeat regions are the most potent microtubule-binding segments; this domain is also the core of pathological aggregation
C-terminal region (residues 369-441): Contributes to microtubule binding and influences aggregation; contains important phosphorylation sites; interacts with the N-terminal domain in a "paperclip" conformation that may protect against aggregation
Despite being intrinsically disordered, tau adopts functionally relevant conformations:
Tau's primary function is the stabilization and promotion of microtubule assembly:
Tau modulates the function of molecular motors along microtubule tracks:
Tau has important roles at the synapse beyond axonal transport:
Tau contains 85 potential phosphorylation sites (45 serine, 35 threonine, 5 tyrosine). Normal tau carries 2-3 moles of phosphate per mole of protein; in AD, this increases to 7-8 moles (tau hyperphosphorylation):
Key kinases:
Key phosphatases:
Key phospho-epitopes as biomarkers:
| Modification | Sites/Description | Effect |
|---|---|---|
| Acetylation | K174, K274, K280, K281 (by p300/CBP) | Inhibits degradation, promotes aggregation; K280 acetylation is an early event in tauopathies |
| Ubiquitination | Multiple lysines | Targets tau for proteasomal degradation; pathological tau is ubiquitinated in NFTs |
| SUMOylation | K340 | May inhibit ubiquitination, reducing clearance |
| Truncation | D421 (caspase-3), E391 (unknown protease) | Generates pro-aggregation fragments; D421-cleaved tau is found in early NFTs |
| Glycosylation | O-GlcNAcylation at multiple sites | Inversely related to phosphorylation (reciprocal regulation); reduced O-GlcNAcylation promotes hyperphosphorylation |
| Nitration | Tyr18, Tyr29, Tyr197, Tyr394 | Mediated by peroxynitrite; promotes oligomerization |
| Methylation | Multiple lysine residues | May compete with ubiquitination, affecting clearance |
Tau aggregation follows a nucleation-elongation mechanism:
Cryo-EM has revealed that different tauopathies feature structurally distinct tau filament folds:
These structural differences define the molecular identity of each tauopathy and have implications for diagnostics and therapeutics.
Tau spreads through the brain via a [prion-like mechanism]:
Tau interacts with other misfolded proteins:
| Biomarker | Specimen | Clinical Utility |
|---|---|---|
| Total tau (t-tau | CSF | Reflects neuronal injury; elevated in AD and rapid dementias (CJD) |
| [p-tau181] | CSF, plasma | AD-specific; distinguishes AD from non-AD dementias |
| p-tau217 | CSF, plasma | Highest diagnostic accuracy for AD; tracks amyloid and tau pathology |
| p-tau231 | CSF, plasma | Changes early; correlates with amyloid PET positivity |
| MTBR-tau243 | CSF | Specific for tau tangle pathology; useful for primary tauopathies |
| Non-phosphorylated tau (NP-tau | CSF | Reflects active tau aggregation |
The study of Tau Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.